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Objectives: We conducted a prospective longitudinal study of plasma cytokines dur-
ing the Mild Cognitive Impairment (MCI) stage of Lewy body disease and Alzheimer's
disease, hypothesizing that cytokine levels would decrease over time and that this
would be correlated with decline in cognition.
Methods: Older (≥60) people with MCI were recruited from memory services in
healthcare trusts in North East England, UK. MCI was diagnosed as due to
Alzheimer's disease (MCI-AD) or Lewy body disease (MCI-LB). Baseline and repeat
annual clinical and cognitive assessments were undertaken and plasma samples were
obtained at the same time. Cytokine assays were performed on all samples using the
Meso Scale Discovery V-Plex Plus Proinflammatory Panel 1, which included IFNγ, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNFα.
Results: Fifty-six patients (21 MCI-AD, 35 MCI-LB) completed prospective evalua-
tions and provided samples up to 3 years after baseline. Six cytokines (IFNγ, IL-1β, IL-
2, IL-4, IL-6 and IL-10) showed highly significant (P < .002) decreases over time. AD
and LB did not differ in rate of decrease nor were there any effects related to age or
general morbidity. Decrease in five of these cytokines (IFNγ, IL-1β, IL-2, IL-4, and IL-
10) was highly correlated with decrease in cognition (P < .003).
Conclusions: Peripheral inflammation decreased in both disease groups during MCI
suggesting this may be a therapeutic window for future anti-inflammatory agents.
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1 | INTRODUCTION
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are
the two commonest causes of neurodegenerative dementia. Extensive
evidence indicates their pathophysiology involves central and periph-
eral inflammation. A meta-analysis of 40 studies found increases in
pro-inflammatory cytokines TNFα, IL-6, IL-1β, IL-12 and IL-18 in AD
compared with controls.1 GWAS in AD have identified that genetic
polymorphisms involved in inflammatory processes are risk factors for
AD,2 including for genes coding for IL1β, HLA-DR, CLU, TREM2 and
CR1. PET imaging with PK11195, a measure of cerebral microglial
activation, has reported increased binding in cortical regions in AD
compared with controls,3,4 supporting microglial activation in AD.
Microglia surround, react to and phagocytose Amyloid-beta (Aβ) in cell
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cultures and rodent models of AD.5 Mouse models of AD have shown
that non-steroidal anti-inflammatory drugs reduce the level of Aβ
plaque load,6 providing evidence that modifying peripheral inflamma-
tion in mice reduces AD pathology. Longitudinal studies have found
plasma levels of inflammatory cytokines elevated up to 5 years before
the clinical onset of dementia in AD7 and we previously reported that,
whilst IL-2, IL-4, IL-10 and IL-1β were increased at the mild cognitive
impairment stage of AD (MCI-AD), they were not at the dementia
stage.8 Moreover, raised C-reactive protein (CRP) in midlife has been
associated with a 3-fold increased risk of developing AD up to
25 years later.9
There has been less research on inflammation in DLB but more
work in the related alpha-synucleinopathy Parkinson's disease (PD).
We previously reported in a cross-sectional study significantly higher
IL-1β, IL-4, IL-2 and IL-10 in DLB at the MCI stage (MCI-LB) but not at
the dementia stage.8 In addition, increased disease severity was asso-
ciated with lower levels of IL-1β, IL-2 and IL-4 in both AD and DLB.
Reviews of the literature show PD patients have higher serum levels
of inflammatory markers such as IL-1β, IL-6, IL-8, TNFα, IFNγ and
RANTES10,11 and studies from our centers have also reported that
inflammatory markers predict disease progression in PD.12 Numerous
studies in PD show polymorphisms in several inflammation-related
genes as being risk factors for the disease, including TREM2, IL1β,
TNFα, LRRK2 and HLA-DR.13,14 Two studies of PK11195 in DLB have
reported increased microglial activation in cortical and subcortical
areas15,16 Alpha-synuclein has been shown to induce microglial activa-
tion in cell culture studies,17 and in PD mouse models.18
In summary, inflammation in AD and DLB may pre-date and pos-
sibly even play a role in precipitating the onset of these dementias,
being present at prodromal and earlier stages but then diminishing
with disease progression. However, no previous studies have prospec-
tively examined cytokines in plasma in a longitudinal study in an MCI
population or in LB disease. We therefore conducted a prospective
longitudinal study in which subjects with MCI-LB and MCI-AD were
re-assessed annually including repeating blood samples for analysis of
peripheral inflammation. We hypothesized that in both MCI groups
there would be a significant decrease in inflammatory markers over
time from the elevated level reported previously8 and that this
decrease would correlate with severity of cognitive impairment, as
measured by the Addenbrooke's Cognitive Examination-Revised
(ACE-R).
2 | METHODS
Recruitment and baseline assessment has been detailed previously.8,19
Briefly, patients aged 60 or older were recruited following assess-
ment at local memory services and had a clinical diagnosis of MCI.
Additionally, patients reported one or more clinical symptoms sensi-
tive, but non-specific, to Lewy Body (LB) disease (eg, mood changes,
sleep disturbance, or autonomic symptoms), or service records indi-
cated the presence of any core DLB features. Following consent, par-
ticipants underwent a research level assessment involving a semi-
structured interview, clinical assessment and neurological examination
by the equivalent of a board-certified medical doctor (PCD).
2.1 | Patient assessments
The MDS Unified Parkinson's Disease Rating Scale - Motor Examina-
tion (UPDRS-III), Epworth Sleepiness Scale (ESS), and Geriatric
Depression Scale (GDS) were administered to patients. The Instru-
mental Activities of Daily Living (IADL) scale, North-East Visual Hallu-
cinations Inventory (NEVHI), Neuropsychiatric Inventory (NPI), Mayo
Sleep Questionnaire (MSQ), Clinician Assessment of Fluctuation
(CAF), and Dementia Cognitive Fluctuation Scale (DCFS) were admin-
istered to informants. Clinical Dementia Rating scale (CDR) and
Cumulative Illness Rating Scale for Geriatrics (CIRS-G) were com-
pleted based on the clinical history. A detailed neuropsychological
evaluation was also carried out as reported previously20 which
included the ACE-R. All subjects were offered dopaminergic imaging
with FP-CIT SPECT at baseline, including those with MCI-AD. Images
were randomized, coded, and then visually rated as normal/abnormal
by an experienced consensus panel blind to clinical information and
diagnosis as reported earlier21 and incorporated into diagnoses.
2.2 | Clinical diagnosis
A three-person consensus clinical panel of experienced Board Certi-
fied old age psychiatrists (AJT, PCD, JPT) independently reviewed
clinical notes taken from the baseline assessment and confirmed diag-
noses of MCI according to NIA-AA criteria.22 This was based on evi-
dence of minimal functional impairment (independent living was
maintained) and a CDR of 0 or 0.5, and the presence of subjective and
objective cognitive decline. Anyone with dementia was excluded. To
determine the etiology, the presence or absence of core LB symptoms
were also rated by the panel, in accordance with the fourth consensus
criteria for DLB.23 Based on health service clinical notes and imaging
results, those with possible significant vascular or frontotemporal
Key points
• Inflammatory cytokines were previously observed to be
elevated in MCI relative to both healthy older adults and
those with dementia
• This was the case in both Lewy body and Alzheimer's
diseases
• In this follow-up study, the increased inflammation in
MCI subsided as this progressed in severity
• Inflammatory processes may represent a potential early
therapeutic target in common neurodegenerative
diseases
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etiologies, or parkinsonism pre-dating cognitive impairment by more
than 1 year, were also excluded. Where possible, an informant was
sought (spouse, friend, or family member) to provide additional infor-
mation. FP-CIT findings were later incorporated into diagnoses but
the panel decisions on MCI and symptoms were made blind to these
findings.
Participants received a diagnosis of MCI with probable
Alzheimer's disease (MCI-AD) when they had no core LB symptoms, a
normal FP-CIT scan and evidence of decline which was characteristic
of AD, with no evidence for another etiology, that is, they met the
additional NIA-AA criterion of “etiology of MCI consistent with AD
pathophysiologic process.”22 MCI with Lewy bodies (MCI-LB) was
diagnosed when at least one core feature was present or the patient
had an abnormal FP-CIT scan, in accordance with current consensus
research criteria for the diagnosis of MCI-LB.24 One participant did
not consent to dopaminergic transporter imaging but had sufficient
clinical LB symptomology for a MCI-LB diagnosis (two core features)
without confirmatory biomarkers.
2.3 | Prospective evaluation
Participants were re-assessed every 12 months by a research nurse
and/or doctor in a prospective longitudinal design, with the above
assessment instruments repeated each year. Clinical assessments
were undertaken blind to results of cytokine assessments. Core LB
symptom presence and severity of cognitive impairment (MCI or
dementia) were re-appraised at annual follow-ups by the clinical diag-
nostic panel and blood samples were repeated each year.
2.4 | Cytokine analyses
Baseline and repeat venous blood samples were taken from all
patients using EDTA tubes, which were then centrifuged and the
plasma removed. Samples were stored at −80C until assays were
performed. Cytokine assays were performed using the Meso Scale
Discovery V-Plex Plus Proinflammatory Panel 1, which included IFNγ,
IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNFα. Assays
were performed at the Newcastle University BioScreening Core Facil-
ity according to the manufacturer's protocol, and samples were
processed in triplicates. Samples which were under the limit of detec-
tion for a particular cytokine (concentration in pg/mL < 0.05 for IFN
gamma, <0.03 for IL-13, <0.02 for IL-12p70 and <0.01 for all other
cytokines) had cytokine levels which were low enough to be
undistinguishable from background noise, and therefore these sam-
ples were treated as having “zero” levels of that cytokine.
2.5 | Statistical analyses
Longitudinal analyses were undertaken with R software packages
lme4 and lmerTest. Repeated measures correlations were analyzed
with the rmcorr package to account for non-independence of observa-
tions within individuals, and providing greater statistical power than
alternative methods (eg, averaging across repeated observations, or
assessing correlations at each time-point). Linear mixed-effects
models assessed the effects of time (continuous) on cytokine levels,
controlling for the effects of age, gender, concurrent illness (CIRS-G
score), use of anti-inflammatory medications (non-steroidal anti-
inflammatory drugs or steroids), and MCI disease group. The effects
of controlling for baseline cognitive function (ACE-R total score) and
indices of local deprivation were also assessed, but their inclusion did
not improve model fit in any cases. Improvements in model fit were
assessed by likelihood ratio tests, with an alpha level of P < .05. Ran-
dom intercept and time-slopes were included at the subject level, all-
owing for correlation between these where appropriate; fixed and
random non-linear terms for time were also assessed, but did not
improve fit over the linear-only term. Cytokine levels were log trans-
formed as at baseline, and continuous covariates were mean-cen-
tered. For testing our two planned hypotheses in all eight cytokines
(16 planned tests), alpha level was adjusted by 0.05/16 = 0.0031. For
all other factors we applied a Bonferroni correction to adjust the sig-
nificance level to <0.001.
The study has ethical approval from a UK Research Ethics Com-
mittee (NRES Committee North East - Newcastle & North Tyneside 2,
reference: 12/NE/0290). Written informed consent was obtained
from all study participants in accordance with this approval.
3 | RESULTS
Seventy-seven MCI patients (21 MCI-AD, 56 MCI-LB) completed the
baseline assessment and provided blood samples, as reported previ-
ously.19 Of these, 56 (21 MCI-AD, 35 MCI-LB) completed at least one
follow-up assessment and provided blood samples. Those who were
not available for repeated samples had a significantly lower baseline
cognitive function (ACE-R) score (t[33] = −2.854, P = .007), but did
not significantly differ in their baseline cytokine levels. Increased
retention of AD likely reflected the more severe course of DLB.25,26
Differential diagnoses were stable over this time (ie, there were no
cases which changed from MCI-LB to MCI-AD), but of those included
who provided two or more samples, 10 MCI-AD (48%) and 13 MCI-
LB (37%) converted to dementia over the course of assessment. The
baseline characteristics of these 56 patients are provided in Table 1.
MCI-LB were slightly younger and as expected there were sex differ-
ences between the disease groups (more females in AD group) and
minor differences in neuropsychiatric symptoms (higher in the MCI-
LB patients), with scores being modest and consistent with early stage
disease. The two groups did not differ in their levels of motor impair-
ment as assessed with the UPDRS-III, though in the full cohort as pre-
viously described including those lost to follow-up, MCI-LB had
significantly higher scores in this measure.21 As impairments were
“rated as seen,” higher UPDRS-III scores in MCI-AD most likely reflect
non-parkinsonian age-related motor impairments; this is supported by
a moderate association between increasing age and UPDRS-III scores
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in the MCI-AD group (r[21] = 0.56, P = .01), but not in MCI-LB (r
[35] = 0.23, P = .18). Sixteen (46%) of the MCI-LB group had abnormal
FP-CIT imaging, while none of the MCI-AD group did. Patient baseline
inflammatory markers are shown in Table 2. As with the larger base-
line group,8 there were no significant differences in baseline cytokine
levels between the diagnostic groups.
3.1 | Prospective evaluation of cytokines in MCI
We repeated at least one annual review for each patient with the lon-
gest follow-up being at 3 years after baseline assessment (four assess-
ments and samples). The mean (SD) time from baseline sample to final
sample was 1.51(0.66) years and we obtained a median of two sam-
ples per patient (minimum 2 and maximum 4). Of the 10 cytokines
evaluated in the Meso Scale panel, two were not included in statistical
analyses because either too many samples had undetectable levels
(IL-13) or the inter-assay variability was too high (IL-12p70). For the
remaining cytokines, the inter-assay % coefficients of variation were:
IFNγ, 5.99%; IL-10, 9.59%; IL-1β, 10.45%; IL-2, 11.69%; IL-4,
9.73%; IL-6, 8.12%, IL-8, 8.95% and TNF-alpha, 7.61%.
3.2 | Change in cytokines over time
Figure 1 shows the change in the remaining eight cytokines over
this period and Table 3 shows the findings from the linear mixed
effects models. Six cytokines (IFNγ, IL-1β, IL-2, IL-4, IL-6 and IL-10)
showed highly significant decreases over time. Four of these (IL-1β,
IL-2, IL-4 and IL-10) had been significantly higher than controls at
baseline.8 IFNγ and IL-6 were not significantly different from con-
trols at baseline but there was high variability in these cytokines,
TABLE 1 Baseline demographics and clinical assessments
MCI-AD (n = 21) MCI-LB (n = 35) P value df
Age (Years ± SD) 78.2 ± 7.8 73.6 ± 7.3 .039 40
Sex (M:F) 7:14 26:9 .005
MMSE (Score ± SD) 26.4 ± 2.2 26.7 ± 2.1 .648 41
ACE-R (Score ± SD) 80.0 ± 10.8 82.1 ± 9.2 .472 37
UPDRS (Score ± SD) 15.8 ± 6.9 18.3 ± 12.1 .318 54
NPI (Score ± SD) 6.6 ± 7.1 12.9 ± 9.9 .014 40a
Antiparkinsonian medication use (Count, %) 0 (0%) 3 (9%) .284
Anti-dementia medication use (Count, %) 5 (24%) 12 (34%) .551
Anti-inflammatory medication use (Count, %) 11 (52%) 20 (57%) .786
CIRS-G (Score ± SD) 9.1 ± 3.1 9.8 ± 4.7 .504 53
Note: Results presented as Welch's t test for continuous variables, and Fisher's exact tests for categorical variables.
aNPI completed where informant was available for 16 MCI-AD and 34 MCI-LB.
Abbreviations: ACE-R, Addenbrooke's Cognitive Examination-Revised; CIRS-G, Cumulative Illness Rating Scale – Geriatric; MCI, mild cognitive impairment;
MCI-AD, MCI with probable Alzheimer's disease; MCI-LB, MCI with Lewy bodies; MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory
Total Score; UPDRS, Unified Parkinson's Disease Rating Scale Part III.
TABLE 2 Baseline inflammatory
markers
Inflammatory marker MCI-AD (n = 21) MCI-LB (n = 35) Valid samples (%) Pa
IFNγ, pg/L (Mean ± SD) 10.04 ± 13.22 6.39 ± 3.84 56 (100%) .691
IL-10, pg/L (Mean ± SD) 0.95 ± 3.5 0.88 ± 0.32 56 (100%) .582
IL-1β, pg/L (Mean ± SD) 2.70 ± 1.37 2.23 ± 1.43 55 (98%) .174
IL-2, pg/L (Mean ± SD) 3.55 ± 0.69 3.52 ± 0.94 56 (100%) .866
IL-4, pg/L (Mean ± SD) 0.87 ± 0.10 0.80 ± 0.22 56 (100%) .090
IL-6, pg/L (Mean ± SD) 2.09 ± 1.20 4.03 ± 4.81 12 (21%) .604b
IL-8, pg/L (Mean ± SD) 3.85 ± 2.46 4.29 ± 2.60 46 (82%) .904
TNFα, pg/L (Mean ± SD) 2.87 ± 3.50 2.49 ± 1.86 51 (91%) .795
Note: Descriptive statistics for raw data, analysis conducted on log-transformed data.
aMann-Whitney U test for non-normally distributed measures.
bWelch's t test for normally distributed measures after transform.
Abbreviations: IFNγ, interferon gamma; IL, interleukin; MCI, mild cognitive impairment; MCI-AD, MCI
with probable Alzheimer's disease; MCI-LB, MCI with Lewy bodies; TNFα, tumour necrosis factor alpha.
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reflected in large standard deviations. Both IL-8 and TNFα were not
different at baseline, and had no significant increase or decrease
over time in MCI. Consistent with the baseline information, the
MCI diagnostic groups did not significantly differ in their inflamma-
tory trajectories.
3.3 | Correlations of cytokines with decrease in
cognition
Examining our second hypothesis, in the overall group we found sig-
nificant positive correlations within individuals (r values between 0.35
F IGURE 1 Predicted effects of time
and diagnostic group on log transformed
cytokine levels over the course of MCI,
including interaction term with shaded
95% confidence intervals. Y-axes scaled
to value range for each cytokine. P-values
for overall time effect. IFNγ, interferon
gamma; MCI, mild cognitive impairment;
MCI-AD, MCI with probable Alzheimer's
disease; MCI-LB, MCI with Lewy bodies;
IL, interleukin; TNFα, tumour necrosis
factor alpha [Colour figure can be viewed
at wileyonlinelibrary.com]
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TABLE 3 Linear mixed effects models for longitudinal change in cytokine levels
Markera Coefficientb SE df t P
IFNγ
Intercept (MCI-AD) 0.76 0.09 53.74 8.702 < .001
Time (years) −0.16 0.03 27.10 −5.069 < .001
Age (years) 0.01 0.01 48.94 1.089 .282
Gender (male) −0.14 0.09 48.46 −1.571 .123
CIRS-G 0.004 0.01 49.72 0.345 .732
Anti-inflammatory use 0.06 0.09 49.60 0.628 .533
MCI-LB vs MCI-AD 0.00 0.09 48.91 −0.052 .959
IL-10
Intercept (MCI-AD) −0.15 0.06 101.99 −2.457 .016
Time (years) −0.26 0.04 38.75 −6.333 < .001
Age (years) −0.01 0.004 105.59 −2.317 .023
Gender (male) 0.04 0.06 111.53 0.581 .563
CIRS-G 0.003 0.01 111.17 0.482 .631
Anti-inflammatory use −0.004 0.06 107.74 −0.056 .955
MCI-LB vs MCI-AD −0.01 0.06 111.05 −0.120 .905
IL-1β
Intercept (MCI-AD) 0.24 0.10 77.97 2.282 .025
Time (years) −1.10 0.09 37.11 −11.746 < .001
Age (years) −0.003 0.01 80.50 −0.359 .720
Gender (male) 0.02 0.11 83.45 0.175 .861
CIRS-G 0.0001 0.01 77.24 0.006 .995
Anti-inflammatory use −0.03 0.11 83.56 −0.246 .806
MCI-LB vs MCI-AD −0.05 0.11 82.19 −0.460 .646
IL-2
Intercept (MCI-AD) 1.06 0.22 84.66 4.771 < .001
Time (years) −1.77 0.14 28.03 −12.658 < .001
Age (years) −0.004 0.01 94.71 −0.310 .758
Gender (male) −0.05 0.22 99.72 −0.244 .808
CIRS-G −0.001 0.02 99.36 −0.061 .952
Anti-inflammatory use −0.17 0.21 99.47 −0.779 .438
MCI-LB vs MCI-AD −0.01 0.23 97.96 −0.040 .968
IL-4
Intercept (MCI-AD) −0.22 0.19 59.27 −1.176 .244
Time (years) −1.38 0.25 25.14 −5.600 < .001
Age (years) −0.02 0.01 58.35 −1.404 .166
Gender (male) −0.21 0.20 58.12 −1.046 .300
CIRS-G −0.01 0.02 59.08 −0.490 .626
Anti-inflammatory use 0.32 0.20 58.81 1.651 .104
MCI-LB vs MCI-AD −0.26 0.21 58.95 −1.256 .214
IL-6
Intercept (MCI-AD) 0.13 0.22 66.50 0.571 .570
Time (years) −0.24 0.07 44.70 −3.231 .002
Age (years) −0.001 0.01 50.77 −0.067 .947
Gender (male) −0.08 0.22 48.60 −0.355 .724
CIRS-G 0.03 0.03 49.43 1.237 .222
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and 0.57) between worsening of cognitive impairment (decrease in
ACE-R) and decrease in cytokine levels for IFNγ, IL-1β, IL-2, IL-4 and
IL-10 (see Table 4). IL-8 had a weak non-significant correlation in the
opposite direction (increasing cytokine level associated with lower
cognition) and there was no correlation for IL-6 and TNFα.
Regarding other potential relationships with cytokine changes,
there were no differences between the disease groups in any of the
changes in cytokine levels nor were there significant effects due to
age or sex or general illness burden (as measured by the CIRS-G) or
use of anti-inflammatory drugs. There was also no correlation
between change in cytokine levels and severity of parkinsonism (mea-
sured using UPDRS).
The data that support the findings of this study are available by
request through Dementias Platform UK at https://portal.
dementiasplatform.uk/DAMatrix.27
4 | DISCUSSION
Our primary hypotheses based on previous literature, that there
would be a decline in plasma cytokine levels in people with MCI due
to AD and DLB over time and that such a decrease would correlate
with the accompanying decline in cognition, were both supported by
our analyses. These findings suggest there may be a therapeutic win-
dow for use of anti-inflammatory drugs in these two major neurode-
generative diseases including this MCI stage of these illnesses.
Both AD and DLB have cholinergic deficits and respond well to
cholinesterase inhibitors and both show modest benefits with
memantine.28 However, there are no disease modifying treatments
available for either disease, with a large number of trials having failed
to demonstrate benefits.29,30 Identification of new therapies for these
devastating diseases is a major priority and targeting neu-
roinflammation is an attractive alternative therapeutic approach. Pre-
vious evidence from genetics in AD,2 and Lewy body disease14 and
TABLE 3 (Continued)
Markera Coefficientb SE df t P
Anti-inflammatory use 0.17 0.22 50.79 0.792 .432
MCI-LB vs MCI-AD −0.09 0.23 50.21 −0.379 .706
IL-8
Intercept (MCI-AD) 1.56 0.12 65.49 12.546 < .001
Time (years) 0.08 0.05 32.63 1.674 .104
Age (years) 0.003 0.01 55.46 0.427 .671
Gender (male) −0.01 0.11 43.54 −0.081 .935
CIRS-G 0.02 0.01 46.59 1.484 .145
Anti-inflammatory use −0.01 0.12 53.34 −0.091 .928
MCI-LB vs MCI-AD −0.10 0.12 49.38 −0.836 .407
TNFα
Intercept (MCI-AD) 0.42 0.15 83.05 2.758 .007
Time (years) 0.14 0.08 43.77 1.729 .091
Age (years) 0.003 0.01 64.27 0.322 .748
Gender (male) −0.11 0.11 45.66 −1.022 .312
CIRS-G 0.01 0.01 49.05 1.039 .304
Anti-inflammatory use 0.24 0.12 64.32 2.004 .049
MCI-LB vs MCI-AD 0.13 0.12 44.30 1.118 .270
aInflammatory marker.
bCoefficients presented are unstandardized. Age and CIRS-G are mean-centered.
Abbreviations: CIRS-G, Cumulative Illness Rating Scale – Geriatric; IFNγ, interferon gamma; IL, interleukin; MCI, mild cognitive impairment; MCI-AD, MCI
with probable Alzheimer's disease; MCI-LB, MCI with Lewy bodies; TNFα, tumour necrosis factor alpha.
TABLE 4 Repeated measures correlations between inflammatory
cytokines and ACE-R
Marker (Log transformed)
ACE-R Total Score
r P
IFNγ 0.353 .002
IL-10 0.494 <.001
IL-1 0.470 .002
IL-2 0.522 <.001
IL-4 0.566 .003
IL-6 −0.044 .810
IL-8 −0.266 .030
TNFα −0.087 .479
Abbreviations: ACE-R, Addenbrooke's Cognitive Examination-Revised;
IFNγ, interferon gamma; IL, interleukin; TNFα, tumour necrosis factor
alpha.
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peripheral measures of inflammation in milder AD1 and LBD10 sup-
ports a role for inflammatory processes in both diseases. We previ-
ously reported that whilst by the dementia stage cytokine levels had
returned to the level of healthy controls, they were elevated at the
MCI stage in both diseases.8,19 This is consistent with other evidence
that inflammatory markers appear to be increased years before the
development of AD dementia,9 though no studies seem to have
assessed MCI-AD. To our knowledge there have been no previous
prospective studies of inflammation in DLB, and the only previous
prospective studies in PD have been from our centers in people with-
out cognitive impairment, which have supported a role for peripheral
inflammation in disease progression in PD.12 In addition, a CSF study
in PD which did not include anyone with dementia but found increas-
ing levels of the inflammatory marker YKL-40, a marker of macro-
phages, which correlated with cognitive decline.31 These patients are
difficult to compare with those in our study and likely represent a dif-
ferent phase of LB disease since they had had many years of motor
LB disease at study entry.
The few PET studies of neuroinflammation have used microglial
markers and found evidence for inflammation in the brain in AD3,4
and DLB.15,16 In the latter study cerebral inflammation was higher in
mild compared with moderate/severe DLB and the microglial activa-
tion was also found to be positively associated with cognitive perfor-
mance.16 Uncertainty about the activation state the microglia are in
and the specificity of these PET microglial markers makes detailed
interpretation and comparison of these studies difficult and may con-
tribute to inconsistencies in findings, as may the modest patient num-
bers in such studies. However, overall a large body of evidence
suggests that in diseases such as AD and DLB there is both central
and peripheral inflammation and that systemic inflammation can drive
neurodegeneration and exacerbate clinical symptoms.32,33 Indeed,
Perry and Teeling have described a concept where increased periph-
eral inflammation can accelerate neurodegeneration via a number of
different mechanisms.33
There is now increasing focus on targeting inflammation as a
treatment for AD and our findings suggest such treatments could be
extended to DLB. Several epidemiological studies have demonstrated
the protective effects of non-steroidal anti-inflammatory drugs in
reducing incidence of AD34,35 and a more recent study showed that
users of disease modifying anti-rheumatic drugs for rheumatoid arthri-
tis were at reduced risk of dementia (hazard ratio of 0.60).36 However,
several randomized controlled trials have failed to show any signifi-
cant benefits for anti-inflammatory drugs.37-39 Intriguingly, post-hoc
analysis of the ADAPT trial revealed that treatment of asymptomatic
individuals did reduce AD incidence, but only with at least 2 to 3 years
of treatment.40 Such results fit with our study findings indicating that
a therapeutic window for such treatments may exist prior to later dis-
ease at the dementia stage. This likely begins before the MCI stage
but MCI currently represents the most realistic window of therapeutic
opportunity during which patients might be identified for such treat-
ment. Such potential benefits from anti-inflammatory medication
might also be targeted at earlier pre-symptomatic stages of disease
but for practical purposes, since MCI is now widely diagnosed in
memory services, such patients are a more realistic group to choose
for clinical trials.
Our study benefits from thorough clinical evaluation and detailed
diagnostic assessments of all the patients and the prospective annual
re-evaluation and diagnostic re-assessment of all patients with follow-
up up to 3 years from baseline. Repeat samples were not available
from either the cognitively healthy or dementia comparison groups.
Controls would not be expected to change and since the dementia
cytokine levels were already low then they had limited scope for
decline but comparison with these in future assessments would clarify
how quickly MCI cytokine levels subside to the levels observed in
dementia. A clear limitation is the modest numbers in each group,
though the highly significant nature of our findings and consistencies
between cytokines does not suggest a lack of power for our primary
outcomes. We were also not able to adequately assess two of our
cytokines (IL-13 and IL-12p70) due to difficulties in accurate detec-
tion of these molecules and as expected people with more cognitive
impairment at baseline and with LB disease, which is a more severe ill-
ness,25,26 were less likely to complete follow-up assessments; 38% of
MCI-LB from baseline were unavailable to provide repeat samples.
These did not differ in their baseline inflammation, but their subse-
quent inflammatory trajectories are unknown, and could differ from
those who were observed, a limitation of this sample. Furthermore,
whilst our findings measuring cytokines do not indicate differences in
inflammation between AD and DLB, there may nonetheless be real
differences in the immune-inflammatory response between these two
diseases which may be identified by focusing on other aspects of this
complex phenomenon, for example, using flow cytometry to measure
the profile of T-cell lymphocytes.
While there is no reason to believe that these biomarkers pro-
gress in a linear fashion within individuals, non-linear time terms were
not supported in this sample, likely due to the limited number of
observations per person. Future work may benefit from considering
the possibility of heterogeneity within a sample such as this; the
declining trajectory of inflammation observed in this study may
describe the later stages of MCI after peripheral inflammation peaks,
while those at the earlier stages may feature a different inflammatory
trajectory (eg, increasing before decreasing in a non-linear fashion).
With sufficient observations and timespan, different trajectory direc-
tions and shapes may be identifiable with a data-driven longitudinal
clustering method, for example, latent class mixed modeling.
In summary, we found strong evidence for a decrease in periph-
eral inflammation in both AD and LBD from elevated levels of cyto-
kines at the MCI stage towards healthy control levels typical of the
dementia stages of these diseases, findings which have important
implications for the design, conduct and outcome measures of future
anti-dementia trials involving putative anti-inflammatory agents.
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